Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, a combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The call will be accessible via phone and webcast through the company's website, with dial-in details provided upon registration. A replay will be available for 30 days following the call.

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE^® with atezolizumab in non-small cell lung cancer.

The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link 
https://register.vevent.com/register/BI9c2d6fa7af764cb7b550c5ce464ce5cf, and you will be provided with dial-in details and a pin number.

Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE^®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE^® are generated on the Company’s proprietary ROCK^® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed (AFMD) present AFM24-102 clinical data for non-small cell lung cancer?

Affimed will present the clinical data during a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET.

What is the focus of Affimed's AFM24-102 trial?

AFM24-102 is a combination trial studying AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer patients.

How can investors access Affimed's AFM24-102 clinical data presentation?

Investors can access the presentation via phone by registering through the provided link or through a live audio webcast on Affimed's website in the Investors section.